FIELD: medicine.
SUBSTANCE: that is ensured by using an enzyme immunoassay to measure patient's oral fluid biomarkers prior to or at least 30 min after meals. The above biomarker is matrix metalloproteinase 2 (MMP 2) or matrix metalloproteinase 8 (MMP 8). For a clinical reference group, MMP 2 is adopted as 1.89-2.69 ng/ml; if the observed level is 4.2-6.6 ng/ml, the low adaptation ability is diagnosed; the level of 2.9-3.8 ng/ml shows the complete functional adaptation in the patient suffering dentofacial new growths to removable appliances of prosthetic dentures. For a clinical reference group, MMP 8 is 21.65-41.85 ng/ml; if the observed level is 433.0-1,011.6 ng/ml, the low adaptation ability is diagnosed; the level of 52.8-186.3 ng/ml shows the complete functional adaptation in the patient suffering dentofacial new growths to removable appliances of prosthetic dentures.
EFFECT: invention provides the higher instant diagnostic accuracy of the adaptation ability to wear removable appliances of prosthetic dentures in the patients suffering dentofacial new growths on the day of visit.
3 cl, 6 ex
